We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+45.75%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$396M
AUM Growth
+$81.5M
(+26%)
Cap. Flow
-$53.8M
Cap. Flow
% of AUM
-13.59%
Top 10 Holdings %
Top 10 Hldgs %
82.26%
Holding
45
New
14
Increased
6
Reduced
5
Closed
12
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
1.9
quarters
Top 20 Avg Time Held Equity + Options
1.7
quarters
Avg Time Held Equity only
2.1
quarters
Top 10 Avg Time Held Equity only
2.1
quarters
Top 20 Avg Time Held Equity only
2.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
+$12.6M |
| 2 |
CytomX Therapeutics
CTMX
|
+$10.5M |
| 3 |
Fate Therapeutics
FATE
|
+$9.28M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$7.47M |
| 5 |
Tempest Therapeutics
TPST
|
+$5.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$19.8M |
| 2 |
Ardelyx
ARDX
|
+$18.6M |
| 3 |
Kyntra Bio
KYNB
|
+$15.7M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$15M |
| 5 |
Editas Medicine
EDIT
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.89% |
| 2 | Miscellaneous | 14.11% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Bristol-Myers Squibb
BMY
$118B
| $928K | 0.23% |
17,060
+8,500
| +99% | +$466K |
2016 Q4
1 quarter
|
|
27
DELISTED
ChemoCentryx, Inc.
CCXI
| $859K | 0.22% |
+118,000
| New | +$850K |
2017 Q1
0 quarters
|
|
28
Syndax Pharmaceuticals
SNDX
$1.23B
| $484K | 0.12% |
35,301
-238,561
| -87% | -$2.48M |
2016 Q1
4 quarters
|
|
|
CASC
29
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $430K | 0.11% |
103,800
| – | – |
2016 Q3
2 quarters
|
|
|
OREX
30
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $405K | 0.1% |
+117,726
| New | +$465K |
2017 Q1
0 quarters
|
|
31
Wave Life Sciences
WVE
$615M
| $275K | 0.07% |
+10,000
| New | +$279K |
2017 Q1
0 quarters
|
|
|
FWP
32
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $108K | 0.03% |
+718
| New | +$135K |
2017 Q1
0 quarters
|
|
|
33
Ardelyx
ARDX
$813M
| – | – |
-1,310,023
| Closed | -$18.6M | – |
|
34
Cytokinetics
CYTK
$8.68B
| – | – |
-54,879
| Closed | -$667K | – |
|
|
35
Editas Medicine
EDIT
$370M
| – | – |
-626,762
| Closed | -$10.2M | – |
|
36
Fastenal
FAST
$57.3B
| – | – |
-10,148,104
| Closed | -$6.37M | – |
|
37
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-1,415,687
| Closed | -$6.51M | – |
|
|
TMBR
38
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
| – | – |
-89
| Closed | -$502K | – |
|
|
ALXN
39
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-162,200
| Closed | -$19.8M | – |
|
|
FPRX
40
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-298,712
| Closed | -$15M | – |
|
|
AGN
41
CALL
DELISTED
Allergan plc
AGN
| – | – |
-50,000
| Closed | -$10.5M | – |
|
42
DELISTED
Dermira, Inc.
DERM
| – | – |
-43,200
| Closed | -$1.31M | – |
|
|
EGLT
43
DELISTED
Egalet Corporation
EGLT
| – | – |
-222,300
| Closed | -$1.7M | – |
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q1 2017 Portfolio in Review
As of Q1 2017, EcoR1 Capital held 45 positions worth $396M, up 26% from $314M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
EcoR1 Capital withdrew a net $53.8M in Q1 2017, closing 12 positions and reducing 5 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, EcoR1 Capital opened a new position in Cascadian Therapeutics, Inc. worth $12.4M.
- EcoR1 Capital's largest Q1 2017 buy was Cascadian Therapeutics, Inc.: 3,000,000 shares worth $12.4M.
- EcoR1 Capital added most to Aclaris Therapeutics in Q1 2017, an estimated $7.47M increase.
- EcoR1 Capital's biggest Q1 2017 reduction was Kyntra Bio, cutting an estimated $15.7M.
- EcoR1 Capital fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $19.8M.
- EcoR1 Capital's ten largest holdings make up 82% of its $396M portfolio in Q1 2017.
- EcoR1 Capital opened 14 new positions and closed 12 in Q1 2017.
- EcoR1 Capital's portfolio value rose 26% quarter-over-quarter to $396M.
Based on EcoR1 Capital's 13F filing for Q1 2017, filed 15 May 2017.